Treatment patterns and clinical outcomes in Chinese patients with NSCLC with <em>MET</em> alterations resistant to EGFR‑TKI therapy

Shen,Cailu; Zhang,Siying; Wang,Xiaoli; Shen,Di; Ge,Xiaosong; Mao,Yong

doi:10.3892/mco.2025.2876

Treatment patterns and clinical outcomes in Chinese patients with NSCLC with MET alterations resistant to EGFR‑TKI therapy

Authors:
- Cailu Shen
- Siying Zhang
- Xiaoli Wang
- Di Shen
- Xiaosong Ge
- Yong Mao
View Affiliations

Affiliations: Department of Cancer Diagnosis and Treatment Center, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214000, P.R. China, Wuxi Medical College of Jiangnan University, Wuxi, Jiangsu 214000, P.R. China, Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214000, P.R. China
Published online on: July 4, 2025 https://doi.org/10.3892/mco.2025.2876
Article Number: 81
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study evaluated therapeutic strategies and clinical outcomes in Chinese patients with mesenchymal‑epithelial transition (MET) alterations in non‑small cell lung cancer (NSCLC) who were progressing on epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI), aiming to address the unmet need of overcoming MET‑driven resistance. A real‑world study was conducted, involving eligible patients with NSCLC treated at Jiangnan University Affiliated Hospital between February 2022 and April 2024. Based on the treatment regimen, patients were categorized into three groups: MET‑TKI combined with EGFR‑TKI, chemotherapy‑based regimen, and other regimens. The primary outcomes were the objective response rate (ORR), time to treatment failure (TTF), post‑progression survival (PPS) and adverse events (AEs). A total of 32 patients were included in the analysis. The MET‑TKI plus EGFR‑TKI group (n=10) achieved the highest ORR at 55.6%, followed by the chemotherapy‑based regimen group (n=15) at 42.9% and the other regimens group (n=7) at 14.3%. The median TTF was 9.5 months for the MET‑TKI plus EGFR‑TKI group, compared with 4.4 and 3.6 months for the chemotherapy‑based and other regimens groups, respectively (P=0.748). Similarly, the median PPS was 14.4 months in the MET‑TKI plus EGFR‑TKI group, compared with 9.4 and 7.0 months in the chemotherapy‑based and other regimens groups, respectively (P=0.733). Treatment‑related AEs varied among the groups, with nausea, peripheral edema and rash being the most common in the MET‑TKI plus EGFR‑TKI group. In conclusion, the combination of MET‑TKI and EGFR‑TKI demonstrates promising benefits in terms of TTF, PPS and ORR, underscoring its potential as a viable treatment option. The modest improvements observed, coupled with the inherent limitations of the present study, emphasize the necessity for further research to optimize treatment strategies and gain a deeper understanding of the long‑term efficacy of combination therapy in addressing MET‑driven resistance to EGFR‑TKI.

View Figures

View References

1	Beaudet M, Lacasse Y and Labbé C: Palliative systemic therapy given near the end of life for metastatic non-small cell lung cancer. Curr Oncol. 29:1316–1325. 2022.PubMed/NCBI View Article : Google Scholar
2	Ichikawa M, Muramatsu N, Matsunaga W, Ishikawa T, Okuda T, Okamoto H and Gotoh A: Effects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesothelioma. Sci Rep. 12(8634)2022.PubMed/NCBI View Article : Google Scholar
3	Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, et al: Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study. World J Surg Oncol. 15(197)2017.PubMed/NCBI View Article : Google Scholar
4	Dong Y, Li Q, Miao Q and Li D: Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review. Medicine (Baltimore). 100(e26450)2021.PubMed/NCBI View Article : Google Scholar
5	Zhu Y, Guo YB, Xu D, Zhang J, Liu ZG, Wu X, Yang XY, Chang DD, Xu M, Yan J, et al: A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD). Ann Transl Med. 9(545)2021.PubMed/NCBI View Article : Google Scholar
6	Liu HE, Vuppalapaty M, Wilkerson C, Renier C, Chiu M, Lemaire C, Che J, Matsumoto M, Carroll J, Crouse S, et al: Detection of EGFR mutations in cfDNA and CTCs, and comparison to tumor tissue in non-small-cell-lung-cancer (NSCLC) patients. Front Oncol. 10(572895)2020.PubMed/NCBI View Article : Google Scholar
7	Chen H, Yang D, Wang Y, Tao H, Luo Y, Wu A, Li S, Yang Z and Chen M: Activation of the Hedgehog pathway mediates resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer. J Cancer. 13:987–997. 2022.PubMed/NCBI View Article : Google Scholar
8	Xu M, Xie Y, Ni S and Liu H: The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med. 3(96)2015.PubMed/NCBI View Article : Google Scholar
9	Peng KC, Su JW, Xie Z, Wang HM, Fang MM, Li WF, Chen YQ, Guan XH, Su J, Yan HH, et al: Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp-untreated patients with advanced non-small cell lung cancer. Thorac Cancer. 13:1619–1630. 2022.PubMed/NCBI View Article : Google Scholar
10	Calabrese F, Pezzuto F, Lunardi F, Fortarezza F, Tzorakoleftheraki SE, Resi MV, Tiné M, Pasello G and Hofman P: Morphologic-molecular transformation of oncogene addicted non-small cell lung cancer. Int J Mol Sci. 23(4164)2022.PubMed/NCBI View Article : Google Scholar
11	Qin K, Hong L, Zhang J and Le X: MET amplification as a resistance driver to TKI therapies in lung cancer: Clinical challenges and opportunities. Cancers (Basel). 15(612)2023.PubMed/NCBI View Article : Google Scholar
12	Feng W, Xie Q, Liu S, Ji Y, Li C, Wang C and Jin L: Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer. Cancer Sci. 109:1775–1786. 2018.PubMed/NCBI View Article : Google Scholar
13	Hu X, Zheng X, Yang S, Wang L, Hao X, Cui X, Ding L, Mao L, Hu P and Shi Y: First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 13(6)2020.PubMed/NCBI View Article : Google Scholar
14	Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JCH, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, et al: Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 36:3101–3109. 2018.PubMed/NCBI View Article : Google Scholar
15	Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, et al: Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): An open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 8:1132–1143. 2020.PubMed/NCBI View Article : Google Scholar
16	Overbeck TR, Cron DA, Schmitz K, Rittmeyer A, Körber W, Hugo S, Schnalke J, Lukat L, Hugo T, Hinterthaner M, et al: Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Transl Lung Cancer Res. 9:603–616. 2020.PubMed/NCBI View Article : Google Scholar
17	Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, et al: Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): A multicentre, open-label, phase 2 trial. Lancet Oncol. 25:989–1002. 2024.PubMed/NCBI View Article : Google Scholar
18	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010.PubMed/NCBI View Article : Google Scholar
19	Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.PubMed/NCBI View Article : Google Scholar
20	Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 378:113–125. 2018.PubMed/NCBI View Article : Google Scholar
21	Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 41:2869–2876. 2023.PubMed/NCBI View Article : Google Scholar
22	Zhou S, Ren F and Meng X: Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy. Front Immunol. 13(955944)2022.PubMed/NCBI View Article : Google Scholar
23	Jiang K, Wu L, Zheng X, Xu Y, Miao Q, Zheng X, Zhang L, Huang C and Lin G: Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: A retrospective dual-center study. BMC Pulm Med. 24(96)2024.PubMed/NCBI View Article : Google Scholar
24	Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, et al: First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol. 30:3002–3011. 2012.PubMed/NCBI View Article : Google Scholar
25	Auliac JB, Chouaid C, Greillier L, Monnet I, Le Caer H, Falchero L, Corre R, Descourt R, Bota S, Berard H, et al: Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. Lung Cancer. 85:415–419. 2014.PubMed/NCBI View Article : Google Scholar
26	Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, et al: Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A randomized phase 3 trial. J Thorac Oncol. 16:1512–1522. 2021.PubMed/NCBI View Article : Google Scholar
27	Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, et al: BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 33:2197–2204. 2015.PubMed/NCBI View Article : Google Scholar
28	Ma L, Diao B, Huang Z, Wang B, Yu J and Meng X: The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Commun (Lond). 41:1314–1330. 2021.PubMed/NCBI View Article : Google Scholar
29	Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, et al: AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 40:3162–3171. 2022.PubMed/NCBI View Article : Google Scholar
30	Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, et al: Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): A multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 10:1019–1028. 2022.PubMed/NCBI View Article : Google Scholar
31	Asami K, Ando M, Nishimura T, Yokoi T, Tamura A, Minato K, Mori M, Ogushi F, Yamamoto A, Yoshioka H, et al: A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). Thorac Cancer. 13:1827–1836. 2022.PubMed/NCBI View Article : Google Scholar
32	Chen Y, Liu Z, An N, Zhang J, Meng W, Wang W, Wu X, Hu X, Chen Y and Yin W: Platelet-derived mitochondria attenuate 5-FU-induced injury to bone-associated mesenchymal stem cells. Stem Cells Int. 2023(7482546)2023.PubMed/NCBI View Article : Google Scholar